#Novartis Pre-Earnings: Results from Q1 2020
The company reported a 22% increase in operating income but the driver behind this positive number - cut in R&amp;D spending in Innovative Medicines, is a negative process.
#investing #stocks #earnings https://t.co/PKZKVlwQok